<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948099</url>
  </required_header>
  <id_info>
    <org_study_id>VIB1116.P1.S1</org_study_id>
    <nct_id>NCT04948099</nct_id>
  </id_info>
  <brief_title>A Study of Single Ascending Doses of VIB1116 in Rheumatic Diseases</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study to evaluate the safety and tolerability of escalating, single&#xD;
      subcutaneous or IV doses of VIB1116 in adult participants with rheumatic diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, randomized, double-blind, placebo-controlled study to evaluate the&#xD;
      safety and tolerability of single, escalating doses of VIB1116 in subjects with certain&#xD;
      rheumatic diseases. After a screening period, eligible subjects will be randomized in a 3:1&#xD;
      ratio, overall, to receive a single dose of VIB1116 or placebo administered as a subcutaneous&#xD;
      (under the skin) or intravenous (in the vein) injection. Some subjects will be observed&#xD;
      overnight in an observation unit after dosing. Subjects will have visits a minimum of monthly&#xD;
      until the end of follow-up, which is a minimum of 85 to 141 days and a maximum of 337 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events, serious adverse events, and adverse events of special interest</measure>
    <time_frame>Up to Day 141</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of VIB1116 and noncompartmental PK parameters</measure>
    <time_frame>Up to Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the blood levels of plasmacytoid dendritic cells</measure>
    <time_frame>Up to Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who are ADA (antidrug antibody) positive</measure>
    <time_frame>Up to Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum and maximum titer in ADA positive participants</measure>
    <time_frame>Up to Day 141</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dendritic Cell -Mediated Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>VIB1116</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of VIB1116, SC or IV administration on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of Placebo, SC or IV administration on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIB1116</intervention_name>
    <description>VIB1116</description>
    <arm_group_label>VIB1116</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years of age and ≤ 60 years of age and a body mass index (BMI) &lt;&#xD;
             30 kg/m² or, in patients who have completed dosing with a vaccine against COVID-19 and&#xD;
             are at least 1 month post the final dose, ≤ 65 years of age and BMI &lt; 35 kg/m^2&#xD;
&#xD;
          -  A diagnosis of one of a specified list of rheumatologic diseases at least 6 months&#xD;
             prior to screening.&#xD;
&#xD;
          -  Stable dosing of glucocorticoid or disease-modifying antirheumatic drugs (DMARDs) used&#xD;
             for treatment of rheumatologic disease for ≥ 28 days prior to randomization.&#xD;
&#xD;
          -  Willing to practice study-required contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planning to change treatment for rheumatologic disorder within 4 months after&#xD;
             randomization&#xD;
&#xD;
          -  Known immunodeficiency disorder or history of splenectomy, organ or cell-based&#xD;
             transplantation, total lymphoid irradiation or T-cell vaccination or transfusion in&#xD;
             prior 6 months&#xD;
&#xD;
          -  Treatment with prednisone or equivalent at a dose &gt; 10 mg/day or intraarticular,&#xD;
             intravenous or intramuscular steroids within 28 days prior to screening&#xD;
&#xD;
          -  Treatment with any of the following medications within 28 days prior to screening&#xD;
             (unless otherwise specified below):&#xD;
&#xD;
               -  Mycophenolate mofetil &gt; 2 g/day&#xD;
&#xD;
               -  Methotrexate &gt; 20 mg/week&#xD;
&#xD;
               -  Leflunomide &gt; 20 mg/day within 6 months prior to screening or receipt of&#xD;
                  leflunomide in combination with any dose of methotrexate&#xD;
&#xD;
               -  Azathioprine &gt; 2 mg/kg/day&#xD;
&#xD;
               -  Cyclosporine (except eye drops); tacrolimus (except topical), sirolimus,&#xD;
                  thalidomide, lenalidomide, 6-mercaptopurine, or voclosporin&#xD;
&#xD;
               -  Hydroxychloroquine &gt; 400 mg/day&#xD;
&#xD;
               -  Chloroquine &gt; 250 mg/day&#xD;
&#xD;
               -  Quinacrine &gt; 100 mg/day&#xD;
&#xD;
               -  Sulfasalazine &gt; 3 g/day, except that no more than 1 g/day is permitted if used in&#xD;
                  combination with methotrexate&#xD;
&#xD;
               -  Dapsone &gt; 100 mg/day&#xD;
&#xD;
               -  Danazol &gt; 800 mg/day&#xD;
&#xD;
               -  Any other nonbiologic immunosuppressive/immunomodulatory agent not already&#xD;
                  specified (eg, mizoribine, retinoids, adrenocorticotropic hormone analogs,&#xD;
                  dehydroepiandrosterone [DHEA]) within 2 weeks prior to screening.&#xD;
&#xD;
               -  Receipt of any biologic B cell-depleting therapy within 12 months or&#xD;
                  non-depleting B cell-directed therapy within 6 months&#xD;
&#xD;
               -  Receipt of abatacept, etanercept, or other biologic immunomodulatory agent or&#xD;
                  immunoglobulins within 3 months&#xD;
&#xD;
               -  Receipt of any other biologic disease modifying antirheumatic drug (bDMARD) not&#xD;
                  already specified, such as any targeted therapy (other than Janus kinase [JAK]&#xD;
                  inhibitor), or receipt of cyclophosphamide or chlorambucil within 6 months&#xD;
&#xD;
               -  Receipt of JAK inhibitors within 3 months&#xD;
&#xD;
               -  Receipt of anticoagulants other than anti-platelet drugs in prior 28 days&#xD;
&#xD;
               -  Active malignancy, history of malignancy within prior 10 years (limited&#xD;
                  exceptions) or known first degree relative with a hereditary cancer syndrome&#xD;
                  unless the patient is known to be free of the predisposing genetic mutation&#xD;
&#xD;
               -  Receipt of live vaccine or live therapeutic infectious agent within the 28 days&#xD;
                  prior to screening.&#xD;
&#xD;
               -  Pregnancy, lactation, or planning to become pregnant before the end of study&#xD;
                  follow-up.&#xD;
&#xD;
          -  Hepatitis B or C infection, HIV infection, evidence of active TB or being at high risk&#xD;
             for TB&#xD;
&#xD;
          -  History of any severe herpes virus infection (including any history of severe&#xD;
             Epstein-Barr virus, cytomegalovirus disease, end-organ disease, disseminated herpes&#xD;
             simplex, disseminated zoster, or ophthalmic zoster) or &gt; 1 episode of herpes zoster in&#xD;
             the 2 years prior to screening and/or any opportunistic infection in the prior 2 years&#xD;
&#xD;
          -  Infection requiring parenteral antimicrobial therapy within 60 days of screening or&#xD;
             any clinically significant active or suspected infection ( within 28 days prior to&#xD;
             screening&#xD;
&#xD;
          -  History of anaphylaxis to any human immunoglobulin therapy or monoclonal antibody.&#xD;
&#xD;
          -  Blood tests at screening (performed in the central laboratory) that meet study&#xD;
             requirements including but not limited to normal coagulation testing and glomerular&#xD;
             filtration rate &lt; 50 mL/min/1.73&#xD;
&#xD;
          -  High risk for COVID-19 or for severe COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzy Hammel, MSHS</last_name>
    <role>Study Director</role>
    <affiliation>Horizon Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horizon Therapeutics</last_name>
    <phone>1-866-479-6742</phone>
    <email>clinicaltrials@horizontherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Fields</last_name>
      <email>rfields@pinnacletrials.com</email>
    </contact>
    <investigator>
      <last_name>Vishala Chindalore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Frazier</last_name>
      <phone>205-975-9564</phone>
      <email>thomasfrazier@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Walter Chatham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of W FL</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765-2616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maartje Brucculeri, MSc</last_name>
      <phone>727-466-0078</phone>
      <phone_ext>223</phone_ext>
      <email>mbrucculeri@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Robert Levin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216-4362</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Smith, RN</last_name>
      <phone>904-732-9254</phone>
      <email>rsmith@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Steven Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-8445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Earnest</last_name>
      <phone>814-693-0300</phone>
      <phone_ext>202</phone_ext>
      <email>brendaearnest@altoonaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alan Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SW Rheumatology Center</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150-6919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guadalupe Cindo</last_name>
      <phone>972-288-2600</phone>
      <phone_ext>106</phone_ext>
      <email>gcindo@swrr.net</email>
    </contact>
    <investigator>
      <last_name>Atul Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maristelle Co</last_name>
      <phone>210-949-0122</phone>
      <email>mco@cttexas.com</email>
    </contact>
    <investigator>
      <last_name>Pendleton Wickersham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune disease</keyword>
  <keyword>Rheumatic disease</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

